Search clinical trials for: Meningococcal vaccines

Total 3850 results

Novartis Vaccines
GlaxoSmithKline

Completed

Persistence of Antibody Response to N. Meningitidis Group C in Children

Prevention of Meningococcal Infection

Spain, Poland
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Hepatitis B | Hepatitis A | Meningococcal Disease | Meningococcal Meningitis

Germany
Novartis Vaccines
GlaxoSmithKline

Completed

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Prevention of the Meningococcal Disease

Germany
Biogen

Completed

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Relapsing Forms of Multiple Sclerosis

United States
Novartis
Novartis Vaccines

Completed

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Meningococcal Disease | Meningococcal Meningitis

Poland
Harvard Pilgrim Health Care
Kaiser Permanente; Aetna, Inc.; i3 Drug Safety; HealthCore, Inc.; Highmark Blue Cross...

Completed

Safety Study of GBS Following Menactra Meningococcal Vaccination

Guillain-Barre Syndrome

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Meningococcal Disease

Italy, Poland, Russian Federation, Spain, United Kingdom
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
GlaxoSmithKline

Completed

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
Novartis Vaccines

Withdrawn

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older

Meningococcal Disease
Novartis Vaccines

Completed

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Meningococcal Disease

United States
University of Oxford

Completed

Understanding the Immune Response to Two Different Meningitis Vaccines

Meningitis | Meningococcal Disease | Septicaemia

United Kingdom
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
University Hospitals Bristol and Weston NHS Foundation...
Public Health England; University of Bristol; Novartis Vaccines; North Bristol...

Completed

Regulation of Mucosal Immune Response to Systemic MenB Vaccine

Meningococcal Infections

United Kingdom
Novartis Vaccines

Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Meningococcal Disease

United States, Poland
GlaxoSmithKline

Completed

Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine

Infections, Meningococcal

Germany, Austria
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guizhou Center for Disease Control... and other collaborators

Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Meningitis | Meningococcal Infections | Meningococcal Meningitis

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Air Force Military Medical University, China; Guangxi Center for Disease Control... and other collaborators

Unknown

Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

Meningitis, Meningococcal

China
Beijing Chaoyang District Centre for Disease Control...

Unknown

Safety and Immunogenicity Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old

ACYW135 Meningococcal Polysaccharide Vaccine
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

Pertussis | Tetanus | Human Papillomavirus Infection | Meningococcal Meningitis

Costa Rica
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Chile
Novartis Vaccines

Completed

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Meningococcal Disease | Meningococcal Meningitis

Spain, Brazil, Hungary, Peru
Novartis Vaccines

Completed

Novartis Vaccine and Diagnostics Carriage Trial

N. Meningitidis Carriage

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Immunology and Safety of Menactra® in Children in Saudi Arabia

Meningitis | Meningococcemia

Saudi Arabia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Puerto Rico
JN-International Medical Corporation

Completed

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Meningococcal Disease

Italy
Novartis Vaccines

Completed

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Meningococcal Infections

Canada, United States
Novartis Vaccines

Completed

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Prevention of Meningococcal Disease

United States
Jiangsu Province Centers for Disease Control and...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines

Hepatitis A

China
University of Oxford
GlaxoSmithKline; Oxford University Hospitals NHS Trust

Completed

Can we Reduce the Number of Vaccine Injections for Children? (MALTA)

Invasive Meningococcal Disease

United Kingdom
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Meningococcal Meningitis

Finland, Poland
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Meningococcal Disease

Italy
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Meningococcal Disease

Korea, Republic of
Novartis Vaccines

Completed

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Healthy

United Kingdom
Beijing Minhai Biotechnology Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

Meningitis

China
Beijing Minhai Biotechnology Co., Ltd

Completed

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine

Meningitis

China
Novartis
Novartis Vaccines

Completed

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

Influenza, Human

Finland, Italy, Germany
Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States
Novartis Vaccines

Completed

Safety Surveillance of MenACWY-CRM Vaccine in Children

Meningococcal Disease

United States
National Institute on Aging (NIA)

Completed

PPV: Pneumococcal Polysaccharide Vaccine in Older Adults

Aging

United States
Novartis Vaccines
Novartis

Completed

A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

Meningococcal Disease | Meningococcal Meningitis

United States
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

Meningococcal Sero-type C Infection

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Meningococcal Infections | Neisseria Meningitidis

Saudi Arabia
Pfizer

Completed

Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Neisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)

Germany
Pfizer

Completed

NeisVac-C Single Prime Study in Infants

Neisseria Meningitidis

Poland, Spain
Pfizer

Completed

Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants

Meningitis, Meningococcal

Austria, Germany
JN-International Medical Corporation

Completed

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Meningitis, Meningococcal

Poland, Spain, Australia

3

Subscribe